Simon Cooper compensation by year
Keros Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $464,423 | $469,808 | $116,099 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,659,196 | $1,561,306 | $1,633,436 |
| Non-equity incentive | $184,000 | $206,800 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $5,848 | $7,683 | $11,240 |
| Total | $2,313,467 | $2,245,597 | $1,760,775 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Keros Therapeutics, Inc. DEF 14A filed April 23, 2025, accession 0001104659-25-037982, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Keros Therapeutics, Inc. filed document, accession 0001104659-25-037982. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 26,250 | — | $34.98 |
| Option | 40,000 | — | $54.38 |
| Option | 28,125 | — | $46.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Keros Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Keros Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Christopher Rovaldi | President and Chief Operating Officer | $6,975,416 |
| Jasbir Seehra | Chief Executive Officer and Chair | $6,273,192 |
| Yung Chyung | Chief Medical Officer | $5,641,367 |
| Keith Regnante | Chief Financial Officer | $2,292,177 |
| Simon Cooper · this page | Former Chief Medical Officer | $1,760,775 |
The full Keros Therapeutics compensation record
free company briefThis page is one person within Keros Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Keros Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Keros Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.